A cross-sectional study of the forearm bone density of long-term users of levonorgestrel-releasing intrauterine system
- PMID: 16373404
- DOI: 10.1093/humrep/dei457
A cross-sectional study of the forearm bone density of long-term users of levonorgestrel-releasing intrauterine system
Abstract
Background: There are concerns about the effect of hormonal contraceptives on bone mineral density (BMD), but there is currently no information available on the effect of the levonorgestrel-releasing intrauterine system (LNG-IUS) on BMD. The objective of this study was to compare the BMD of LNG-IUS users with that of controls using the TCu380A intrauterine device (IUD).
Materials and methods: A cross-sectional study paired 53 women, aged 25-51 years, who had been using the LNG-IUS for 7 years, with 53 IUD users, according to age (+/-1 year) and body mass index (BMI; kg/m2) (+/-1). BMD was evaluated at the midshaft of the ulna and the distal radius of the nondominant forearm using double X-ray absorptiometry.
Results: Mean age of women was 34 years. BMI was slightly over 25 in both groups. Estradiol was normal. Mean BMD was 0.469 +/- 0.008 and 0.467 +/- 0.009 and 0.409 +/- 0.009 and 0.411 +/- 0.009 at the midshaft of the ulna and distal radius in LNG-IUS and IUD users, respectively, without significant differences.
Conclusions: Women aged 25-51 years, using the LNG-IUS for 7 years, had a mean BMD similar to that of the control group of TCu380A IUD users.
Similar articles
-
Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system.Hum Reprod. 2010 May;25(5):1158-64. doi: 10.1093/humrep/deq043. Epub 2010 Feb 25. Hum Reprod. 2010. PMID: 20185512
-
Body weight and composition in users of levonorgestrel-releasing intrauterine system.Contraception. 2012 Oct;86(4):350-3. doi: 10.1016/j.contraception.2012.01.017. Epub 2012 Mar 23. Contraception. 2012. PMID: 22445431
-
A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate.Contraception. 2011 Nov;84(5):e31-7. doi: 10.1016/j.contraception.2011.06.012. Epub 2011 Aug 10. Contraception. 2011. PMID: 22018135
-
The levonorgestrel intrauterine system in nulliparous women.Contraception. 2007 Jun;75(6 Suppl):S12-5. doi: 10.1016/j.contraception.2007.01.018. Epub 2007 Apr 3. Contraception. 2007. PMID: 17531602 Review.
-
The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception.Contraception. 2012 Mar;85(3):224-34. doi: 10.1016/j.contraception.2011.08.003. Epub 2011 Sep 19. Contraception. 2012. PMID: 22067761 Review.
Cited by
-
Role of the levonorgestrel intrauterine system in effective contraception.Patient Prefer Adherence. 2013 Aug 9;7:777-85. doi: 10.2147/PPA.S36948. eCollection 2013. Patient Prefer Adherence. 2013. PMID: 23990713 Free PMC article.
-
Hormonal Contraception and Bone Health in Adolescents.Front Endocrinol (Lausanne). 2020 Aug 21;11:603. doi: 10.3389/fendo.2020.00603. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32973688 Free PMC article. Review.
-
Vaginally administered PEGylated LIF antagonist blocked embryo implantation and eliminated non-target effects on bone in mice.PLoS One. 2011;6(5):e19665. doi: 10.1371/journal.pone.0019665. Epub 2011 May 18. PLoS One. 2011. PMID: 21611124 Free PMC article.
-
U.S. Medical Eligibility Criteria for Contraceptive Use, 2024.MMWR Recomm Rep. 2024 Aug 8;73(4):1-126. doi: 10.15585/mmwr.rr7304a1. MMWR Recomm Rep. 2024. PMID: 39106314 Free PMC article.
-
Update on hormonal contraception and bone density.Rev Endocr Metab Disord. 2011 Jun;12(2):93-106. doi: 10.1007/s11154-011-9180-6. Rev Endocr Metab Disord. 2011. PMID: 21559817 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical